O-RAN ALLIANCE Displays Growing Momentum and Potential of AI through Spring PlugFest and MWC Shanghai
The O-RAN ALLIANCE (O-RAN), fulfilling its mission to transform Radio Access Networks to be open, intelligent, virtualized and fully interoperable, today announced the successful completion of the O-RAN Global PlugFest Spring 2023. This event, involving major operators, carried out critical testing and validation of O-RAN technologies to support and encourage ongoing adoption by the industry. In addition, O-RAN has unveiled a lineup of demonstrations that highlight the latest advancements, on-site at MWC Shanghai, or online at the O-RAN ALLIANCE Virtual Exhibition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230612575935/en/
O-RAN Global PlugFest Spring 2023
The O-RAN Global PlugFest Spring 2023 was conducted from April to June 2 in ten labs across Asia, Europe and North America, with 60 participating companies or institutions. The tests provided participants validation of O-RAN equipment conformance, performance and interoperability; tackled issues and overcome hurdles to wider technology adoption; and facilitated exploration of new features, scenarios and applications.
“The sheer scale of participation in O-RAN PlugFests is testament to industry support and momentum of deployment,” said Alex Jinsung Choi, Chair of the Board of O-RAN ALLIANCE and SVP Group Technology, Deutsche Telekom. “In the Spring 2023 PlugFest, we expanded the ecosystem by testing products from new vendors. Participants validated the security of end-to-end O-RAN architecture and demonstrated the power of the RIC to support critical use cases such as quality of service and energy efficiency.”
O-RAN ALLIANCE welcomes support of the PlugFest from its membership community and would like to give thanks to the participants listed later in this press release.
Latest Innovations of O-RAN Technology to Be Demonstrated in MWC Shanghai and Virtually
O-RAN companies plan to showcase 3 on-site and 15 virtual demonstrations, including innovations such as indoor positioning applications, cloud economics with 5G and AI applications, intelligent RAN control, machine learning load balancing, and energy-efficient network deployment solutions.
The demos reveal the incredible potential of AI in enhancing energy efficiency and load balancing, and demonstrate the ability to effectively validate the security of O-RAN networks. Additionally, there are impressive exhibits featuring energy-efficient technology for indoor network deployment and a comprehensive solution for 5G Radio Unit testing. These groundbreaking advances will revolutionize the telecom industry, reflecting the O-RAN ALLIANCE’s unwavering dedication to fostering a more open, intelligent, and efficient RAN.
These demonstrations, featuring contributions from top tech companies, highlight the O-RAN ALLIANCE's dedication to creating a more open and efficient future RAN. Through the utilization of advanced technologies such as AI, cloud solutions, and machine learning, the O-RAN ALLIANCE is leading the way toward substantial enhancements in network performance, security, and energy efficiency.
Visit O-RAN demonstrations showcased at MWC Shanghai 2023:
- O-RAN Energy-efficiency technology by Intel and partner in hall N2, stand B13 (TietoEVRY)
- O-RAN-based integrated base stations by Sageran in hall N1, stand B124 and hall N3, stand E93 (Sageran)
- O-RAN testing solutions by Rohde & Schwarz, VIAVI Solutions and Baicells in hall N1, stand E90 (Baicells)
For more details, please read our web announcement. The demos will soon appear at the O-RAN ALLIANCE Virtual Exhibition.
O-RAN ALLIANCE would like to give recognition to the latest demonstration additions from: Aarna Networks, ArrayComm, Artiza Networks, Baicells, GDCNI, Groundhog, Intel, Inventec, Lenovo, LitePoint, NVIDIA, Radisys, Rohde & Schwarz, Sageran, VIAVI Solutions, Virginia Polytechnical Institute and State University.
Participants in O-RAN Global PlugFest Spring 2023
In South Korea, the PlugFest was hosted by KT in NIA 5G Testbed Center in Pangyo. Participants included: ETRI, Fujitsu, Keysight Technologies, NTT DOCOMO and SOLiD.
In Taiwan, the PlugFest was hosted by Auray OTIC and Security lab in its two locations in Taoyuan and Kaohsiung. Participants included: Anritsu, Askey, Calnex Solutions, Capgemini Engineering, Compal, Institute for Information Industry (III), Inventec, ITRI, Keysight Technologies, LITEON, LitePoint, LIONS, Metanoia Communications, MiTAC Computing Technology, National Taiwan University of Science and Technology (NTUST), Pegatron, Rohde & Schwarz, Quanta Cloud Technology (QCT), SageRAN Technology, TMYTEK, Ultraband Technologies, VIAVI Solutions, Wistron NeWeb Corp, Xena Networks.
In Europe, the PlugFest was jointly hosted by Deutsche Telekom, EANTC, EURECOM, Orange and Vodafone in 3 labs: i14y Lab in Berlin, EURECOM Lab in Sophia Antipolis and Vodafone Central O-RAN Lab in Newbury. Participants included: Benetel, Capgemini Engineering, Dell Technologies, IS-Wireless, LITEON, Net AI, Nokia, Radisys, Red Hat, Rimedo Labs, Rohde & Schwarz, VIAVI Solutions, VMware, VoerEir and Wind River.
In USA, the PlugFest was jointly hosted by University of New Hampshire, COSMOS, CableLabs and POWDER in partnership with AT&T and DISH Network, across 4 labs: University of New Hampshire InterOperability Lab in Durham (NH), North American OTIC in NYC Metro Area/East (COSMOS) in North Brunswick (NJ), CableLabs Kyrio O-RAN Test and Integration Lab in Louisville (CO) and POWDER by University of Utah in Salt Lake City (UT). Participants included: Analog Devices, Calnex Solutions, Capgemini Engineering, EXFO, Fujitsu, highstreet technologies, IP Infusion, National Instruments, Red Hat, Spirent Communications, VIAVI Solutions, Wind River and Xena Networks.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230612575935/en/
Contact information
O-RAN ALLIANCE PR
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom